Clinical management of Staphylococcus aureus bacteraemia

The Lancet Infectious Diseases

Volumn 11, Issue 3, 2011, Pages 208-222

  Thwaites, Guy E ^a   Edgeworth, Jonathan D ^b,c   Gkrania Klotsas, Effrossyni ^d,e   Kirby, Andrew ^e   Tilley, Robert ^f   Török, M Estée ^d   Walker, Sarah ^g,h   Wertheim, Heiman FL ^i,j   Wilson, Peter ^k   Llewelyn, Martin J ^l  

^a IMPERIAL COLLEGE LONDON   (United Kingdom)

^b GUY'S AND ST THOMAS' NHS FOUNDATION TRUST   (United Kingdom)

^c KING'S COLLEGE LONDON   (United Kingdom)

^d ADDENBROOKE S HOSPITAL   (United Kingdom)

^e UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^f UNIVERSITY OF LIVERPOOL   (United Kingdom)

^g ROYAL DEVON AND EXETER HOSPITAL   (United Kingdom)

^h NIHR OXFORD BIOMEDICAL RESEARCH CENTRE   (United Kingdom)

ⁱ OXFORD UNIVERSITY CLINICAL RESEARCH UNIT   (Viet Nam)

^j UNIVERSITY OF OXFORD   (United Kingdom)

^k UNIVERSITY COLLEGE LONDON HOSPITALS   (United Kingdom)

^l BRIGHTON AND SUSSEX MEDICAL SCHOOL   (United Kingdom)

more..

Author keywords

[No Author keywords available]

Indexed keywords

AMIKACIN; BETA LACTAM ANTIBIOTIC; CEFALOTIN; CEFAZOLIN; CEFOTAXIME; CEFTRIAXONE; CIPROFLOXACIN; CLOXACILLIN; DALBAVANCIN; DAPTOMYCIN; DICLOXACILLIN; FLUCLOXACILLIN; GENTAMICIN; LINEZOLID; METICILLIN; NAFCILLIN; NETILMICIN; PENICILLIN G; POLYPEPTIDE ANTIBIOTIC AGENT; PROBENECID; RIFAMPICIN; TEICOPLANIN; TELAVANCIN; TIGECYCLINE; TOBRAMYCIN; VANCOMYCIN;

ANTIBIOTIC RESISTANCE; ANTIBIOTIC THERAPY; BACTERIAL ENDOCARDITIS; BACTERIAL STRAIN; BACTERIUM IDENTIFICATION; CATHETER INFECTION; CLINICAL TRIAL; DRUG EFFICACY; DRUG INDICATION; DRUG TREATMENT FAILURE; HUMAN; LIVER TOXICITY; LONG TERM CARE; LOW DRUG DOSE; MINIMUM INHIBITORY CONCENTRATION; NAUSEA; NEPHROTOXICITY; NONHUMAN; PRIORITY JOURNAL; REVIEW; SKIN INFECTION; SOFT TISSUE INFECTION; STAPHYLOCOCCAL BACTEREMIA; STAPHYLOCOCCUS AUREUS; THROMBOCYTOPENIA; TREATMENT DURATION;

EID: 79952033104     PISSN: 14733099     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1473-3099(10)70285-1     Document Type: Review

References (157)

1. Shorr AF, Tabak YP, Killian AD, Gupta V, Liu LZ, Kollef MH Healthcare-associated bloodstream infection: a distinct entity? Insights from a large U.S. database. Crit Care Med 2006, 34:2588-2595.
2. Voluntary reporting of Staphylococcus aureus bacteraemia in England, Wales, and Northern Ireland January-December UK Health Protection Agency, (accessed Nov 30, 2010). http://www.hpa.org.uk/web/HPAwebFile/HPAweb_C/1258560519595.
3. Wyllie DH, Crook DW, Peto TE Mortality after Staphylococcus aureus bacteraemia in two hospitals in Oxfordshire, 1997-2003: cohort study. BMJ 2006, 333:281.
4. Baddour LM, Wilson WR, Bayer AS, et al. Infective endocarditis: diagnosis, antimicrobial therapy, and management of complications: a statement for healthcare professionals from the Committee on Rheumatic Fever, Endocarditis, and Kawasaki Disease, Council on Cardiovascular Disease in the Young, and the Councils on Clinical Cardiology, Stroke, and Cardiovascular Surgery and Anesthesia, American Heart Association: endorsed by the Infectious Diseases Society of America. Circulation 2005, 111:e394-e434.
5. Elliott TS, Foweraker J, Gould FK, Perry JD, Sandoe JA Guidelines for the antibiotic treatment of endocarditis in adults: report of the Working Party of the British Society for Antimicrobial Chemotherapy. J Antimicrob Chemother 2004, 54:971-981.
6. Gemmell CG, Edwards DI, Fraise AP, Gould FK, Ridgway GL, Warren RE Guidelines for the prophylaxis and treatment of methicillin-resistant Staphylococcus aureus (MRSA) infections in the UK. J Antimicrob Chemother 2006, 57:589-608.
7. Mermel LA, Allon M, Bouza E, et al. Clinical practice guidelines for the diagnosis and management of intravascular catheter-related infection: 2009 update by the Infectious Diseases Society of America. Clin Infect Dis 2009, 49:1-45.
8. Habib G, Hoen B, Tornos P, et al. Guidelines on the prevention, diagnosis, and treatment of infective endocarditis (new version 2009): the Task Force on the Prevention, Diagnosis, and Treatment of Infective Endocarditis of the European Society of Cardiology (ESC). Eur Heart J 2009, 30:2369-2413.
9. Naber CK, Baddour LM, Giamarellos-Bourboulis EJ, et al. Clinical consensus conference: survey on Gram-positive bloodstream infections with a focus on Staphylococcus aureus. Clin Infect Dis 2009, 48(suppl 4):S260-S270.
10. Jensen AG, Wachmann CH, Espersen F, Scheibel J, Skinhoj P, Frimodt-Moller N Treatment and outcome of Staphylococcus aureus bacteremia: a prospective study of 278 cases. Arch Intern Med 2002, 162:25-32.
11. Fowler VG, Olsen MK, Corey GR, et al. Clinical identifiers of complicated Staphylococcus aureus bacteremia. Arch Intern Med 2003, 163:2066-2072.
12. Chang FY, Peacock JE, Musher DM, et al. Staphylococcus aureus bacteremia: recurrence and the impact of antibiotic treatment in a prospective multicenter study. Medicine (Baltimore) 2003, 82:333-339.
13. Johnson LB, Almoujahed MO, Ilg K, Maolood L, Khatib R Staphylococcus aureus bacteremia: compliance with standard treatment, long-term outcome and predictors of relapse. Scand J Infect Dis 2003, 35:782-789.
14. Lesens O, Hansmann Y, Storck D, Christmann D Risk factors for metastatic infection in patients with Staphylococcus aureus bacteremia with and without endocarditis. Eur J Intern Med 2003, 14:227-231.
15. Charlson ME, Pompei P, Ales KL, MacKenzie CR A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis 1987, 40:373-383.
16. Chang FY, MacDonald BB, Peacock JE, et al. A prospective multicenter study of Staphylococcus aureus bacteremia: incidence of endocarditis, risk factors for mortality, and clinical impact of methicillin resistance. Medicine (Baltimore) 2003, 82:322-332.
17. Durack DT, Lukes AS, Bright DK New criteria for diagnosis of infective endocarditis: utilization of specific echocardiographic findings. Duke Endocarditis Service. Am J Med 1994, 96:200-209.
18. Turnidge JD, Kotsanas D, Munckhof W, et al. Staphylococcus aureus bacteraemia: a major cause of mortality in Australia and New Zealand. Med J Aust 2009, 191:368-373.
19. Raad II, Sabbagh MF Optimal duration of therapy for catheter-related Staphylococcus aureus bacteremia: a study of 55 cases and review. Clin Infect Dis 1992, 14:75-82.
20. Siegman-Igra Y, Reich P, Orni-Wasserlauf R, Schwartz D, Giladi M The role of vancomycin in the persistence or recurrence of Staphylococcus aureus bacteraemia. Scand J Infect Dis 2005, 37:572-578.
21. Khatib R, Johnson LB, Fakih MG, et al. Persistence in Staphylococcus aureus bacteremia: incidence, characteristics of patients and outcome. Scand J Infect Dis 2006, 38:7-14.
22. Fowler VG, Sanders LL, Sexton DJ, et al. Outcome of Staphylococcus aureus bacteremia according to compliance with recommendations of infectious diseases specialists: experience with 244 patients. Clin Infect Dis 1998, 27:478-486.
23. Jenkins TC, Price CS, Sabel AL, Mehler PS, Burman WJ Impact of routine infectious diseases service consultation on the evaluation, management, and outcomes of Staphylococcus aureus bacteremia. Clin Infect Dis 2008, 46:1000-1008.
24. Wilson R, Hamburger M Fifteen years' experience with staphylococcus septicemia in a large city hospital; analysis of fifty-five cases in the Cincinnati General Hospital 1940 to 1954. Am J Med 1957, 22:437-457.
25. Guerrero ML Fernandez, Lopez JJ Gonzalez, Goyenechea A, Fraile J, de Gorgolas M Endocarditis caused by Staphylococcus aureus: a reappraisal of the epidemiologic, clinical, and pathologic manifestations with analysis of factors determining outcome. Medicine (Baltimore) 2009, 88:1-22.
26. Murray RJ Staphylococcus aureus infective endocarditis: diagnosis and management guidelines. Intern Med J 2005, 35(suppl 2):S25-S44.
27. Bradbury T, Fehring TK, Taunton M, et al. The fate of acute methicillin-resistant Staphylococcus aureus periprosthetic knee infections treated by open debridement and retention of components. J Arthroplasty 2009, 24(6 suppl):101-104.
28. Davis JS Management of bone and joint infections due to Staphylococcus aureus. Intern Med J 2005, 35(suppl 2):S79-S96.
29. Mylotte JM, Tayara A Staphylococcus aureus bacteremia: predictors of 30-day mortality in a large cohort. Clin Infect Dis 2000, 31:1170-1174.
30. Van Hal SJ, Mathur G, Kelly J, Aronis C, Cranney GB, Jones PD The role of transthoracic echocardiography in excluding left sided infective endocarditis in Staphylococcus aureus bacteraemia. J Infect 2005, 51:218-221.
31. Bayer AS, Lam K, Ginzton L, Norman DC, Chiu CY, Ward JI Staphylococcus aureus bacteremia. Clinical, serologic, and echocardiographic findings in patients with and without endocarditis. Arch Intern Med 1987, 147:457-462.
32. Pigrau C, Rodriguez D, Planes AM, et al. Management of catheter-related Staphylococcus aureus bacteremia: when may sonographic study be unnecessary?. Eur J Clin Microbiol Infect Dis 2003, 22:713-719.
33. Evangelista A, Gonzalez-Alujas MT Echocardiography in infective endocarditis. Heart 2004, 90:614-617.
34. Erbel R, Rohmann S, Drexler M, et al. Improved diagnostic value of echocardiography in patients with infective endocarditis by transoesophageal approach. A prospective study. Eur Heart J 1988, 9:43-53.
35. Shively BK, Gurule FT, Roldan CA, Leggett JH, Schiller NB Diagnostic value of transesophageal compared with transthoracic echocardiography in infective endocarditis. J Am Coll Cardiol 1991, 18:391-397.
36. Shapiro SM, Young E, De Guzman S, et al. Transesophageal echocardiography in diagnosis of infective endocarditis. Chest 1994, 105:377-382.
37. Rozich JD, Edwards WD, Hanna RD, Laffey DM, Johnson GH, Klarich KW Mechanical prosthetic valve-associated strands: pathologic correlates to transesophageal echocardiography. J Am Soc Echocardiogr 2003, 16:97-100.
38. Fowler VG, Li J, Corey GR, et al. Role of echocardiography in evaluation of patients with Staphylococcus aureus bacteremia: experience in 103 patients. J Am Coll Cardiol 1997, 30:1072-1078.
39. Rosen AB, Fowler VG, Corey GR, et al. Cost-effectiveness of transesophageal echocardiography to determine the duration of therapy for intravascular catheter-associated Staphylococcus aureus bacteremia. Ann Intern Med 1999, 130:810-820.
40. Blyth CC, Darragh H, Whelan A, O'Shea JP, Beaman MH, McCarthy JS Evaluation of clinical guidelines for the management of Staphylococcus aureus bacteraemia. Intern Med J 2002, 32:224-232.
41. Sullenberger AL, Avedissian LS, Kent SM Importance of transesophageal echocardiography in the evaluation of Staphylococcus aureus bacteremia. J Heart Valve Dis 2005, 14:23-28.
42. Fortun J, Perez-Molina JA, Anon MT, Martinez-Beltran J, Loza E, Guerrero A Right-sided endocarditis caused by Staphylococcus aureus in drug abusers. Antimicrob Agents Chemother 1995, 39:525-528.
43. Fortun J, Navas E, Martinez-Beltran J, et al. Short-course therapy for right-side endocarditis due to Staphylococcus aureus in drug abusers: cloxacillin versus glycopeptides in combination with gentamicin. Clin Infect Dis 2001, 33:120-125.
44. Calain P, Krause KH, Vaudaux P, et al. Early termination of a prospective, randomized trial comparing teicoplanin and flucloxacillin for treating severe staphylococcal infections. J Infect Dis 1987, 155:187-191.
45. Degener JE, Vogel M, Michel MF, Mutsaers MM, Hop WC The efficacy of the combination of teicoplanin or flucloxacillin with netilmicin in the treatment of Staphylococcus aureus bacteraemia. J Antimicrob Chemother 1989, 23:899-904.
46. Khatib R, Johnson LB, Sharma M, Fakih MG, Ganga R, Riederer K Persistent Staphylococcus aureus bacteremia: incidence and outcome trends over time. Scand J Infect Dis 2009, 41:4-9.
47. Kreisel K, Boyd K, Langenberg P, Roghmann MC Risk factors for recurrence in patients with Staphylococcus aureus infections complicated by bacteremia. Diagn Microbiol Infect Dis 2006, 55:179-184.
48. Walker TM, Bowler IC, Bejon P Risk factors for recurrence after Staphylococcus aureus bacteraemia. A retrospective matched case-control study. J Infect 2009, 58:411-416.
49. Lodise TP, McKinnon PS, Levine DP, Rybak MJ Impact of empirical-therapy selection on outcomes of intravenous drug users with infective endocarditis caused by methicillin-susceptible Staphylococcus aureus. Antimicrob Agents Chemother 2007, 51:3731-3733.
50. Appelbaum PC Reduced glycopeptide susceptibility in methicillin-resistant Staphylococcus aureus (MRSA). Int J Antimicrob Agents 2007, 30:398-408.
51. Tenover FC, Moellering RC The rationale for revising the Clinical and Laboratory Standards Institute vancomycin minimal inhibitory concentration interpretive criteria for Staphylococcus aureus. Clin Infect Dis 2007, 44:1208-1215.
52. Rybak MJ, Leonard SN, Rossi KL, Cheung CM, Sader HS, Jones RN Characterization of vancomycin-heteroresistant Staphylococcus aureus from the metropolitan area of Detroit, Michigan, over a 22-year period (1986 to 2007). J Clin Microbiol 2008, 46:2950-2954.
53. Bae IG, Federspiel JJ, Miro JM, et al. Heterogeneous vancomycin-intermediate susceptibility phenotype in bloodstream methicillin-resistant Staphylococcus aureus isolates from an international cohort of patients with infective endocarditis: prevalence, genotype, and clinical significance. J Infect Dis 2009, 200:1355-1366.
54. Sakoulas G, Moise-Broder PA, Schentag J, Forrest A, Moellering RC, Eliopoulos GM Relationship of MIC and bactericidal activity to efficacy of vancomycin for treatment of methicillin-resistant Staphylococcus aureus bacteremia. J Clin Microbiol 2004, 42:2398-2402.
55. Moise PA, Sakoulas G, Forrest A, Schentag JJ Vancomycin in vitro bactericidal activity and its relationship to efficacy in clearance of methicillin-resistant Staphylococcus aureus bacteremia. Antimicrob Agents Chemother 2007, 51:2582-2586.
56. Soriano A, Marco F, Martinez JA, et al. Influence of vancomycin minimum inhibitory concentration on the treatment of methicillin-resistant Staphylococcus aureus bacteremia. Clin Infect Dis 2008, 46:193-200.
57. Lodise TP, Graves J, Evans A, et al. Relationship between vancomycin MIC and failure among patients with methicillin-resistant Staphylococcus aureus bacteremia treated with vancomycin. Antimicrob Agents Chemother 2008, 52:3315-3320.
58. Liao CH, Chen SY, Huang YT, Hsueh PR Outcome of patients with meticillin-resistant Staphylococcus aureus bacteraemia at an emergency department of a medical centre in Taiwan. Int J Antimicrob Agents 2008, 32:326-332.
59. Musta AC, Riederer K, Shemes S, et al. Vancomycin MIC plus heteroresistance and outcome of methicillin-resistant Staphylococcus aureus bacteremia: trends over 11 years. J Clin Microbiol 2009, 47:1640-1644.
60. Horne KC, Howden BP, Grabsch EA, et al. Prospective comparison of the clinical impacts of heterogeneous vancomycin-intermediate methicillin-resistant Staphylococcus aureus (MRSA) and vancomycin-susceptible MRSA. Antimicrob Agents Chemother 2009, 53:3447-3452.
61. Price J, Atkinson S, Llewelyn M, Paul J Paradoxical relationship between the clinical outcome of Staphylococcus aureus bacteremia and the minimum inhibitory concentration of vancomycin. Clin Infect Dis 2009, 48:997-998.
62. Patel JB, Jevitt LA, Hageman J, McDonald LC, Tenover FC An association between reduced susceptibility to daptomycin and reduced susceptibility to vancomycin in Staphylococcus aureus. Clin Infect Dis 2006, 42:1652-1653.
63. Pillai SK, Wennersten C, Venkataraman L, Eliopoulos GM, Moellering RC, Karchmer AW Development of reduced vancomycin susceptibility in methicillin-susceptible Staphylococcus aureus. Clin Infect Dis 2009, 49:1169-1174.
64. Moise PA, North D, Steenbergen JN, Sakoulas G Susceptibility relationship between vancomycin and daptomycin in Staphylococcus aureus: facts and assumptions. Lancet Infect Dis 2009, 9:617-624.
65. Francioli P, Clement M, Geroulanos S, et al. Ceftazidime in severe infections: a Swiss multicentre study. J Antimicrob Chemother 1983, 12(suppl A):139-146.
66. Chambers HF, Mills J, Drake TA, Sande MA Failure of a once-daily regimen of cefonicid for treatment of endocarditis due to Staphylococcus aureus. Rev Infect Dis 1984, 6(suppl 4):S870-S874.
67. Stryjewski ME, Szczech LA, Benjamin DK, et al. Use of vancomycin or first-generation cephalosporins for the treatment of hemodialysis-dependent patients with methicillin-susceptible Staphylococcus aureus bacteremia. Clin Infect Dis 2007, 44:190-196.
68. Fernandez-Guerrero ML, de Gorgolas M Cefazolin therapy for Staphylococcus aureus bacteremia. Clin Infect Dis 2005, 41:127.
69. Nannini EC, Singh KV, Murray BE Relapse of type A beta-lactamase-producing Staphylococcus aureus native valve endocarditis during cefazolin therapy: revisiting the issue. Clin Infect Dis 2003, 37:1194-1198.
70. Nannini EC, Stryjewski ME, Singh KV, et al. Inoculum effect with cefazolin among clinical isolates of methicillin-susceptible Staphylococcus aureus: frequency and possible cause of cefazolin treatment failure. Antimicrob Agents Chemother 2009, 53:3437-3441.
71. Shah PM Staphylococcus aureus septicaemia treated with cefotaxime. Infection 1985, 13(suppl 1):S34-S36.
72. Fujii R Experience with cefotaxime in infections caused by Gram-positive pathogens, especially Staphylococcus aureus. Infection 1985, 13(suppl 1):S9-S13.
73. Maslow MJ, Levine JF, Pollock AA, Simberkoff MS, Rahal JJ Efficacy of a twelve-hourly ceftriaxone regimen in the treatment of serious bacterial infections. Antimicrob Agents Chemother 1982, 22:103-107.
74. Soriano E, Gatell JM, Aguado JM, et al. Ceftriaxone monotherapy for severe bacteremic infections. Chemotherapy 1989, 35(suppl 2):27-32.
75. File TM, Tan JS, Salstrom SJ Clinical evaluation of ceftriaxone. Clin Ther 1984, 6:653-661.
76. Van Laethem Y, Hermans P, De Wit S, Goosens H, Clumeck N Teicoplanin compared with vancomycin in methicillin-resistant Staphylococcus aureus infections: preliminary results. J Antimicrob Chemother 1988, 21(suppl A):81-87.
77. Gilbert DN, Wood CA, Kimbrough RC Failure of treatment with teicoplanin at 6 milligrams/kilogram/day in patients with Staphylococcus aureus intravascular infection. Antimicrob Agents Chemother 1991, 35:79-87.
78. Wilson AP, Gruneberg RN, Neu H A critical review of the dosage of teicoplanin in Europe and the USA. Int J Antimicrob Agents 1994, 4(suppl 1):1-30.
79. Darley ES, MacGowan AP The use and therapeutic drug monitoring of teicoplanin in the UK. Clin Microbiol Infect 2004, 10:62-69.
80. Svetitsky S, Leibovici L, Paul M Comparative efficacy and safety of vancomycin versus teicoplanin: systematic review and meta-analysis. Antimicrob Agents Chemother 2009, 53:4069-4079.
81. Mylotte JM, McDermott C Staphylococcus aureus bacteremia caused by infected intravenous catheters. Am J Infect Control 1987, 15:1-6.
82. Park KH, Kim SH, Song EH, et al. Development of bacteraemia or fungaemia after removal of colonized central venous catheters in patients with negative concomitant blood cultures. Clin Microbiol Infect 2010, 16:742-746.
83. Jernigan JA, Farr BM Short-course therapy of catheter-related Staphylococcus aureus bacteremia: a meta-analysis. Ann Intern Med 1993, 119:304-311.
84. Rahal JJ, Chan YK, Johnson G Relationship of staphylococcal tolerance, teichoic acid antibody, and serum bactericidal activity to therapeutic outcome in Staphylococcus aureus bacteremia. Am J Med 1986, 81:43-52.
85. Iannini PB, Crossley K Therapy of Staphylococcus aureus bacteremia associated with a removable focus of infection. Ann Intern Med 1976, 84:558-560.
86. Mylotte JM, McDermott C, Spooner JA Prospective study of 114 consecutive episodes of Staphylococcus aureus bacteremia. Rev Infect Dis 1987, 9:891-907.
87. Ehni WF, Reller LB Short-course therapy for catheter-associated Staphylococcus aureus bacteremia. Arch Intern Med 1989, 149:533-536.
88. Malanoski GJ, Samore MH, Pefanis A, Karchmer AW Staphylococcus aureus catheter-associated bacteremia. Minimal effective therapy and unusual infectious complications associated with arterial sheath catheters. Arch Intern Med 1995, 155:1161-1166.
89. Zeylemaker MM, Jaspers CA, van Kraaij MG, Visser MR, Hoepelman IM Long-term infectious complications and their relation to treatment duration in catheter-related Staphylococcus aureus bacteremia. Eur J Clin Microbiol Infect Dis 2001, 20:380-384.
90. Fatkenheuer G, Preuss M, Salzberger B, et al. Long-term outcome and quality of care of patients with Staphylococcus aureus bacteremia. Eur J Clin Microbiol Infect Dis 2004, 23:157-162.
91. Khosrovaneh A, Sharma M, Khatib R Favorable prognosis of Staphylococcus aureus bacteremia originating from soft tissues: a prospective study of fifty cases. Scand J Infect Dis 2005, 37:6-10.
92. Thomas MG, Morris AJ Cannula-associated Staphylococcus aureus bacteraemia: outcome in relation to treatment. Intern Med J 2005, 35:319-330.
93. Ghanem GA, Boktour M, Warneke C, et al. Catheter-related Staphylococcus aureus bacteremia in cancer patients: high rate of complications with therapeutic implications. Medicine (Baltimore) 2007, 86:54-60.
94. Horstkotte D, Follath F, Gutschik E, et al. Guidelines on prevention, diagnosis and treatment of infective endocarditis executive summary; the Task Force on Infective Endocarditis of the European Society of Cardiology. Eur Heart J 2004, 25:267-276.
95. Chambers HF, Miller RT, Newman MD Right-sided Staphylococcus aureus endocarditis in intravenous drug abusers: two-week combination therapy. Ann Intern Med 1988, 109:619-624.
96. Torres-Tortosa M, de Cueto M, Vergara A, et al. Prospective evaluation of a two-week course of intravenous antibiotics in intravenous drug addicts with infective endocarditis. Eur J Clin Microbiol Infect Dis 1994, 13:559-564.
97. Ribera E, Gomez-Jimenez J, Cortes E, et al. Effectiveness of cloxacillin with and without gentamicin in short-term therapy for right-sided Staphylococcus aureus endocarditis. A randomized, controlled trial. Ann Intern Med 1996, 125:969-974.
98. Schrenzel J, Harbarth S, Schockmel G, et al. A randomized clinical trial to compare fleroxacin-rifampicin with flucloxacillin or vancomycin for the treatment of staphylococcal infection. Clin Infect Dis 2004, 39:1285-1292.
99. Heldman AW, Hartert TV, Ray SC, et al. Oral antibiotic treatment of right-sided staphylococcal endocarditis in injection drug users: prospective randomized comparison with parenteral therapy. Am J Med 1996, 101:68-76.
100. Parker RH, Fossieck BE Intravenous followed by oral antimicrobial therapy for staphylococcal endocarditis. Ann Intern Med 1980, 93:832-834.
101. Carney DN, Fossieck BE, Parker RH, Minna JD Bacteremia due to Staphylococcus aureus in patients with cancer: report on 45 cases in adults and review of the literature. Rev Infect Dis 1982, 4:1-12.
102. Chayakul P, Yipintsoi T Intravenous followed by oral antimicrobial therapy for staphylococcal endocarditis. J Med Assoc Thai 1993, 76:559-563.
103. Watanakunakorn C, Baird IM Prognostic factors in Staphylococcus aureus endocarditis and results of therapy with a penicillin and gentamicin. Am J Med Sci 1977, 273:133-139.
104. Abrams B, Sklaver A, Hoffman T, Greenman R Single or combination therapy of staphylococcal endocarditis in intravenous drug abusers. Ann Intern Med 1979, 90:789-791.
105. Korzeniowski O, Sande MA Combination antimicrobial therapy for Staphylococcus aureus endocarditis in patients addicted to parenteral drugs and in nonaddicts: a prospective study. Ann Intern Med 1982, 97:496-503.
106. Cosgrove SE, Vigliani GA, Fowler VG, et al. Initial low-dose gentamicin for Staphylococcus aureus bacteremia and endocarditis is nephrotoxic. Clin Infect Dis 2009, 48:713-721.
107. Hughes DW, Frei CR, Maxwell PR, et al. Continuous versus intermittent infusion of oxacillin for treatment of infective endocarditis caused by methicillin-susceptible Staphylococcus aureus. Antimicrob Agents Chemother 2009, 53:2014-2019.
108. Levine DP, Fromm BS, Reddy BR Slow response to vancomycin or vancomycin plus rifampin in methicillin-resistant Staphylococcus aureus endocarditis. Ann Intern Med 1991, 115:674-680.
109. Riedel DJ, Weekes E, Forrest GN Addition of rifampin to standard therapy for treatment of native valve infective endocarditis caused by Staphylococcus aureus. Antimicrob Agents Chemother 2008, 52:2463-2467.
110. Sande MA, Courtney KB Nafcillin-gentamicin synergism in experimental staphylococcal endocarditis. J Lab Clin Med 1976, 88:118-124.
111. Sande MA Evaluation of antimicrobial agents in the rabbit model of endocarditis. Rev Infect Dis 1981, 3(suppl):S240-S249.
112. Falagas ME, Matthaiou DK, Bliziotis IA The role of aminoglycosides in combination with a beta-lactam for the treatment of bacterial endocarditis: a meta-analysis of comparative trials. J Antimicrob Chemother 2006, 57:639-647.
113. Fowler VG, Boucher HW, Corey GR, et al. Daptomycin versus standard therapy for bacteremia and endocarditis caused by Staphylococcus aureus. N Engl J Med 2006, 355:653-665.
114. Ruotsalainen E, Jarvinen A, Koivula I, et al. Levofloxacin does not decrease mortality in Staphylococcus aureus bacteraemia when added to the standard treatment: a prospective and randomized clinical trial of 381 patients. J Intern Med 2006, 259:179-190.
115. Gransden WR, Eykyn SJ, Phillips I Staphylococcus aureus bacteraemia: 400 episodes in St Thomas's Hospital. BMJ 1984, 288:300-303.
116. Huang YT, Hsiao CH, Liao CH, Lee CW, Hsueh PR Bacteremia and infective endocarditis caused by a non-daptomycin-susceptible, vancomycin-intermediate, and methicillin-resistant Staphylococcus aureus strain in Taiwan. J Clin Microbiol 2008, 46:1132-1136.
117. Howden BP, Ward PB, Charles PG, et al. Treatment outcomes for serious infections caused by methicillin-resistant Staphylococcus aureus with reduced vancomycin susceptibility. Clin Infect Dis 2004, 38:521-528.
118. Whitby M Fusidic acid in septicaemia and endocarditis. Int J Antimicrob Agents 1999, 12(suppl 2):S17-S22.
119. Jones RN, Ross JE, Castanheira M, Mendes RE United States resistance surveillance results for linezolid (LEADER Program for 2007). Diagn Microbiol Infect Dis 2008, 62:416-426.
120. 14C]linezolid to healthy human subjects. Drug Metab Dispos 2001, 29:1136-1145.
121. Stevens DL, Ma Y, Salmi DB, McIndoo E, Wallace RJ, Bryant AE Impact of antibiotics on expression of virulence-associated exotoxin genes in methicillin-sensitive and methicillin-resistant Staphylococcus aureus. J Infect Dis 2007, 195:202-211.
122. Weigelt J, Itani K, Stevens D, Lau W, Dryden M, Knirsch C Linezolid versus vancomycin in treatment of complicated skin and soft tissue infections. Antimicrob Agents Chemother 2005, 49:2260-2266.
123. Wunderink RG, Rello J, Cammarata SK, Croos-Dabrera RV, Kollef MH Linezolid vs vancomycin: analysis of two double-blind studies of patients with methicillin-resistant Staphylococcus aureus nosocomial pneumonia. Chest 2003, 124:1789-1797.
124. Shorr AF, Kunkel MJ, Kollef M Linezolid versus vancomycin for Staphylococcus aureus bacteraemia: pooled analysis of randomized studies. J Antimicrob Chemother 2005, 56:923-929.
125. Falagas ME, Siempos II, Vardakas KZ Linezolid versus glycopeptide or beta-lactam for treatment of Gram-positive bacterial infections: meta-analysis of randomised controlled trials. Lancet Infect Dis 2008, 8:53-66.
126. Sader HS, Watters AA, Fritsche TR, Jones RN Activity of daptomycin and selected antimicrobial agents tested against Staphylococcus aureus from patients with bloodstream infections hospitalized in European medical centers. J Chemother 2008, 20:28-32.
127. Snydman DR, Jacobus NV, McDermott LA, Lonks JR, Boyce JM Comparative in vitro activities of daptomycin and vancomycin against resistant Gram-positive pathogens. Antimicrob Agents Chemother 2000, 44:3447-3450.
128. Pertel PE, Bernardo P, Fogarty C, et al. Effects of prior effective therapy on the efficacy of daptomycin and ceftriaxone for the treatment of community-acquired pneumonia. Clin Infect Dis 2008, 46:1142-1151.
129. Florescu I, Beuran M, Dimov R, et al. Efficacy and safety of tigecycline compared with vancomycin or linezolid for treatment of serious infections with methicillin-resistant Staphylococcus aureus or vancomycin-resistant enterococci: a phase 3, multicentre, double-blind, randomized study. J Antimicrob Chemother 2008, 62(suppl 1):i17-i28.
130. Breedt J, Teras J, Gardovskis J, et al. Safety and efficacy of tigecycline in treatment of skin and skin structure infections: results of a double-blind phase 3 comparison study with vancomycin-aztreonam. Antimicrob Agents Chemother 2005, 49:4658-4666.
131. Noel GJ, Bush K, Bagchi P, Ianus J, Strauss RS A randomized, double-blind trial comparing ceftobiprole medocaril with vancomycin plus ceftazidime for the treatment of patients with complicated skin and skin-structure infections. Clin Infect Dis 2008, 46:647-655.
132. Noel GJ, Strauss RS, Amsler K, Heep M, Pypstra R, Solomkin JS Results of a double-blind, randomized trial of ceftobiprole treatment of complicated skin and skin structure infections caused by Gram-positive bacteria. Antimicrob Agents Chemother 2008, 52:37-44.
133. Jauregui LE, Babazadeh S, Seltzer E, et al. Randomized, double-blind comparison of once-weekly dalbavancin versus twice-daily linezolid therapy for the treatment of complicated skin and skin structure infections. Clin Infect Dis 2005, 41:1407-1415.
134. Raad I, Darouiche R, Vazquez J, et al. Efficacy and safety of weekly dalbavancin therapy for catheter-related bloodstream infection caused by Gram-positive pathogens. Clin Infect Dis 2005, 40:374-380.
135. Falagas ME, Makris GC, Dimopoulos G, Matthaiou DK Heteroresistance: a concern of increasing clinical significance?. Clin Microbiol Infect 2008, 14:101-104.
136. Falagas ME, Manta KG, Ntziora F, Vardakas KZ Linezolid for the treatment of patients with endocarditis: a systematic review of the published evidence. J Antimicrob Chemother 2006, 58:273-280.
137. Wilcox MH, Tack KJ, Bouza E, et al. Complicated skin and skin-structure infections and catheter-related bloodstream infections: noninferiority of linezolid in a phase 3 study. Clin Infect Dis 2009, 48:203-212.
138. Jang HC, Kim SH, Kim KH, et al. Salvage treatment for persistent methicillin-resistant Staphylococcus aureus bacteremia: efficacy of linezolid with or without carbapenem. Clin Infect Dis 2009, 49:395-401.
139. Livermore DM Future directions with daptomycin. J Antimicrob Chemother 2008, 62(suppl 3):iii41-iii49.
140. Warren RE Daptomycin in endocarditis and bacteraemia: a British perspective. J Antimicrob Chemother 2008, 62(suppl 3):iii25-iii33.
141. Sakoulas G, Brown J, Lamp KC, Friedrich LV, Lindfield KC Clinical outcomes of patients receiving daptomycin for the treatment of Staphylococcus aureus infections and assessment of clinical factors for daptomycin failure: a retrospective cohort study utilizing the Cubicin Outcomes Registry and Experience. Clin Ther 2009, 31:1936-1945.
142. Falagas ME, Giannopoulou KP, Ntziora F, Vardakas KZ Daptomycin for endocarditis and/or bacteraemia: a systematic review of the experimental and clinical evidence. J Antimicrob Chemother 2007, 60:7-19.
143. Falagas ME, Giannopoulou KP, Ntziora F, Papagelopoulos PJ Daptomycin for treatment of patients with bone and joint infections: a systematic review of the clinical evidence. Int J Antimicrob Agents 2007, 30:202-209.
144. Sharma M, Riederer K, Chase P, Khatib R High rate of decreasing daptomycin susceptibility during the treatment of persistent Staphylococcus aureus bacteremia. Eur J Clin Microbiol Infect Dis 2008, 27:433-437.
145. Sakoulas G Clinical outcomes with daptomycin: a post-marketing, real-world evaluation. Clin Microbiol Infect 2009, 15(suppl 6):11-16.
146. Sakoulas G, Alder J, Thauvin-Eliopoulos C, Moellering RC, Eliopoulos GM Induction of daptomycin heterogeneous susceptibility in Staphylococcus aureus by exposure to vancomycin. Antimicrob Agents Chemother 2006, 50:1581-1585.
147. Rose WE, Leonard SN, Sakoulas G, et al. Daptomycin activity against Staphylococcus aureus following vancomycin exposure in an in vitro pharmacodynamic model with simulated endocardial vegetations. Antimicrob Agents Chemother 2008, 52:831-836.
148. Cui L, Tominaga E, Neoh HM, Hiramatsu K Correlation between reduced daptomycin susceptibility and vancomycin resistance in vancomycin-intermediate Staphylococcus aureus. Antimicrob Agents Chemother 2006, 50:1079-1082.
149. Sader HS, Fritsche TR, Jones RN Daptomycin bactericidal activity and correlation between disk and broth microdilution method results in testing of Staphylococcus aureus strains with decreased susceptibility to vancomycin. Antimicrob Agents Chemother 2006, 50:2330-2336.
150. Moise PA, Hershberger E, Amodio-Groton MI, Lamp KC Safety and clinical outcomes when utilizing high-dose (> or =8 mg/kg) daptomycin therapy. Ann Pharmacother 2009, 43:1211-1219.
151. Rose WE, Rybak MJ, Kaatz GW Evaluation of daptomycin treatment of Staphylococcus aureus bacterial endocarditis: an in vitro and in vivo simulation using historical and current dosing strategies. J Antimicrob Chemother 2007, 60:334-340.
152. Benvenuto M, Benziger DP, Yankelev S, Vigliani G Pharmacokinetics and tolerability of daptomycin at doses up to 12 milligrams per kilogram of body weight once daily in healthy volunteers. Antimicrob Agents Chemother 2006, 50:3245-3249.
153. Woodford N, Livermore DM Infections caused by Gram-positive bacteria: a review of the global challenge. J Infect 2009, 59(suppl 1):S4-S16.
154. Ammerlaan H, Seifert H, Harbarth S, et al. Adequacy of antimicrobial treatment and outcome of Staphylococcus aureus bacteremia in 9 Western European countries. Clin Infect Dis 2009, 49:997-1005.
155. Bayer AS, Murray BE Initial low-dose aminoglycosides in Staphylococcus aureus bacteremia: good science, urban legend, or just plain toxic?. Clin Infect Dis 2009, 48:722-724.
156. Xiong YQ, Fowler VG, Yeaman MR, Perdreau-Remington F, Kreiswirth BN, Bayer AS Phenotypic and genotypic characteristics of persistent methicillin-resistant Staphylococcus aureus bacteremia in vitro and in an experimental endocarditis model. J Infect Dis 2009, 199:201-208.
157. Edgeworth JD, Yadegarfar G, Pathak S, et al. An outbreak in an intensive care unit of a strain of methicillin-resistant Staphylococcus aureus sequence type 239 associated with an increased rate of vascular access device-related bacteremia. Clin Infect Dis 2007, 44:493-501.